Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16722
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSaha, Poornima-
dc.contributor.authorRegan, Meredith M-
dc.contributor.authorPagani, Olivia-
dc.contributor.authorFrancis, Prudence A-
dc.contributor.authorWalley, Barbara A-
dc.contributor.authorRibi, Karin-
dc.contributor.authorBernhard, Jürg-
dc.contributor.authorLuo, Weixiu-
dc.contributor.authorGómez, Henry L-
dc.contributor.authorBurstein, Harold J-
dc.contributor.authorParmar, Vani-
dc.contributor.authorTorres, Roberto-
dc.contributor.authorStewart, Josephine-
dc.contributor.authorBellet, Meritxell-
dc.contributor.authorPerelló, Antonia-
dc.contributor.authorDane, Faysal-
dc.contributor.authorMoreira, Antonio-
dc.contributor.authorVorobiof, Daniel-
dc.contributor.authorNottage, Michelle-
dc.contributor.authorPrice, Karen N-
dc.contributor.authorCoates, Alan S-
dc.contributor.authorGoldhirsch, Aron-
dc.contributor.authorGelber, Richard D-
dc.contributor.authorColleoni, Marco-
dc.contributor.authorFleming, Gini F-
dc.contributor.authorSOFT and TEXT Investigators-
dc.contributor.authorInternational Breast Cancer Study Group-
dc.date2017-06-27-
dc.date.accessioned2017-07-13T01:34:24Z-
dc.date.available2017-07-13T01:34:24Z-
dc.date.issued2017-09-20-
dc.identifier.citationJournal of Clinical Oncology 2017; 35(27): 3113-3122en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16722-
dc.description.abstractPurpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS. We summarize treatment efficacy, quality of life, and adherence of the cohort of women younger than 35 years in SOFT and TEXT, alongside data from the cohort of older premenopausal women. Results For 240 human epidermal growth factor receptor 2-negative patients younger than 35 years enrolled in SOFT after receiving chemotherapy, the 5-year breast cancer-free interval (BCFI) was 67.1% (95% CI, 54.6% to 76.9%) with tamoxifen alone, 75.9% with tamoxifen plus OFS (95% CI, 64.0% to 84.4%), and 83.2% with exemestane plus OFS (95% CI, 72.7% to 90.0%). For 145 human epidermal growth factor receptor 2-negative patients younger than 35 years in TEXT, 5-year BCFI was 79.2% (95% CI, 66.2% to 87.7%) with tamoxifen plus OFS and 81.6% (95% CI, 69.8% to 89.2%) with exemestane plus OFS. The most prominent quality of life symptom for patients younger than 35 years receiving OFS was vasomotor symptoms, with the greatest worsening from baseline at 6 months (on the order of 30 to 40 points), but loss of sexual interest and difficulties in becoming aroused were also clinically meaningful (≥ 8-point change). The level of symptom burden was similar in older premenopausal women. A total of 19.8% of women younger than 35 years stopped all protocol-assigned endocrine therapy early. Conclusion In women younger than 35 years with hormone receptor-positive breast cancer, adjuvant OFS combined with tamoxifen or exemestane produces large improvements in BCFI compared with tamoxifen alone. Menopausal symptoms are significant but are not worse than those seen in older premenopausal women.en_US
dc.titleTreatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trialsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Clinical Oncologyen_US
dc.identifier.affiliationThe University of Chicago Medical Center, Chicago, IL, USAen_US
dc.identifier.affiliationDana-Farber Cancer Institute, Boston, MA, USAen_US
dc.identifier.affiliationHarvard Medical School, Boston, MA, USAen_US
dc.identifier.affiliationFrontier Science and Technology Research Foundation, Boston, MA, USAen_US
dc.identifier.affiliationHarvard T.H. Chan School of Public Health, Boston, MA, USAen_US
dc.identifier.affiliationInstitute of Oncology of Southern Switzerland, Bern, Switzerlanden_US
dc.identifier.affiliationInternational Breast Cancer Study Group Coordinating Center, Bern, Switzerlanden_US
dc.identifier.affiliationBern University Hospital, Inselspital, Bern, Switzerlanden_US
dc.identifier.affiliationPeter MacCallum Cancer Center, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationSt Vincent's Hospital, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationUniversity of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationUniversity of Newcastle, Newcastle, New South Wales, Australiaen_US
dc.identifier.affiliationUniversity of Sydney, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationRoyal Brisbane Hospital, Brisbane, Queensland, Australiaen_US
dc.identifier.affiliationUniversity of Calgary, Calgary, Alberta, Canadaen_US
dc.identifier.affiliationNational Cancer Institute of Canada, Calgary, Alberta, Canadaen_US
dc.identifier.affiliationInstituto Nacional de Enfermedades Neoplásicas, Lima, Peruen_US
dc.identifier.affiliationTata Memorial Centre, Mumbai, Indiaen_US
dc.identifier.affiliationInstituto Nacional del Cancer, Santiago de Chile, Chileen_US
dc.identifier.affiliationVall d'Hebron Institute of Oncology, Barcelona, Spainen_US
dc.identifier.affiliationVall d'Hebron University Hospital, Barcelona, Spainen_US
dc.identifier.affiliationUniversitat Autònoma de Barcelona, Barcelona, Spainen_US
dc.identifier.affiliationHospital Universitari Son Espases, Palma de Mallorca, Spainen_US
dc.identifier.affiliationMarmara University Hospital, Istanbul, Turkeyen_US
dc.identifier.affiliationInstituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugaen_US
dc.identifier.affiliationSandton Oncology Centre, Johannesburg, South Africaen_US
dc.identifier.affiliationEuropean Institute of Oncology, Milan, Italyen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28654365en_US
dc.identifier.doi10.1200/JCO.2016.72.0946en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.